Validation and psychometric evaluation of the Swedish version of the Nasal Obstruction Symptom Evaluation scale. [PDF]
Sunnergren O +5 more
europepmc +1 more source
Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao +14 more
wiley +1 more source
A rare case of ancient schwannoma of nasal vestibule causing complete nasal obstruction: A case report and brief review of literature. [PDF]
Reta BK +5 more
europepmc +1 more source
Translation and Validation of the Thai Version of the Nasal Obstruction Symptom Evaluation (NOSE) Scale. [PDF]
Prasertwit K +4 more
europepmc +1 more source
Atypical cause of nasal obstruction: a rare case of primary hodgkin lymphoma of thenasopharynx
Mohanad Abusultan, Jozef Beňo
openalex +1 more source
ABSTRACT Background Pseudomonas aeruginosa is an opportunistic pathogen in cystic fibrosis‐related chronic rhinosinusitis (CF‐CRS) that produces phenazine metabolites pyocyanin and 1‐hydroxyphenazine (1‐HP), which may have detrimental effects on mitochondria, reactive oxygen species (ROS), Ca2+ signaling, and apoptosis.
Joel C. Thompson +8 more
wiley +1 more source
Comparison of Cottle-Area-2 and Cottle-Area-3 in Computed Tomography Scans of Patients with Nasal Obstruction and Controls. [PDF]
Heppt H +5 more
europepmc +1 more source
Nasal obstruction in a 14 year old girl caused by a huge middle turbinate mucocele appearing radiologically as an inverted papilloma. [PDF]
Wakeford W, Ioannidis D.
europepmc +1 more source
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol +14 more
wiley +1 more source

